Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours ยท Estimated delivery Aug 10 - Aug 15
TRICARE For Life beneficiaries are seen under their TRICARE benefit, not Medicare
For the primary endpoint, participants taking retatrutide achieved average A1C reductions of up to 2.0% from a baseline of 7.9%
Blood Exendin-4 levels, food intake, body weight, and metabolic parameters were monitored over several months
In the SURMOUNT-1 trial, participants without diabetes achieved an average body weight reduction of up to about 22.5% after 72 weeks at the highest dose, one of the largest reductions reported for a medication in obesity research
US$ 22.42
US$ 20.35
US$ 22.75
US$ 25.99
US$ 22.62
US$ 25.14
US$ 24.19
